Oral anticoagulation in patients with atrial fibrillation and end-stage kidney disease

• Autor(a) principal: Azevedo,Tânia B.
• Data de Publicação: 2022
• Outros Autores: Correia,Sofia
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692022000100057
• topic: Atrial fibrillation; chronic kidney disease; dialysis; end‑stage kidney disease; non‑vitamin K oral anticoagulants; vitamin K antagonists

ABSTRACT Atrial fibrillation is highly prevalent in patients with end‑stage kidney disease. For patients with atrial fibrillation but normal kidney function, the net clinical benefit of oral anticoagulation with vitamin K antagonists and non‑vitamin K oral anticoagulants in preventing stroke against the hemorrhagic risk is well‑known. However, dialysis patients present unique risk factors that increase ischemic stroke and bleeding events that are not included in the traditional risk scores. These points, in addition to the pharmacokinetic issues related to the use of oral anticoagulants in end‑stage kidney disease, raise the question of the safety of these drugs, making it difficult to predict whether the benefit outweighs the risk. Data on this topic in chronic kidney disease stages 4, 5, and 5D patients is sparse and the clinical guidelines are also inconsistente in which is the best approach for these patients. This review gives an overview of the state of the art on this topic, specifically the recommendations of the newest guidelines, then discusses the various risk scores and their pitfalls, and finally summarizes the current knowledge on the possible benefits of Non‑vitamin K oral anticoagulants versus Vitamin K antagonists in dialysis patients.